Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has
shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …

Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …